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Background: Infusion of angiotensin II (AngII) via subcutaneous osmotic pumps into mice promotes the development of
abdominal aortic aneurysms (AAAs). These AngII-induced AAAs develop via a complex process in which there is a
transmedial break, lumen dilation, thrombus formation, inflammation involving cells of both the innate and acquired
immune systems, and remodeling. The recent development of a high-frequency ultrasound machine has permitted the
noninvasive detection of murine abdominal aortas. We assessed the ability of a Visualsonics Vevo 660 high-resolution
imaging system to detect AAAs and sequentially quantify the aortic luminal diameter. This system had 100% accuracy in
detecting AngII-induced AAAs in vivo, with intrauser and interuser variation coefficients of less than 10% for
quantification of the aortic lumen diameter.
Methods:Male apolipoprotein E (apoE)/mice were infused subcutaneously with either saline or AngII and were monitored
with this ultrasonic system to define the temporal changes in aortic lumen diameter. Aortic luminal diameters were measured
in the aneurysm-susceptible region of the suprarenal aorta. For internal controls, abdominal aortic diameters were measured
at the level of the left renal branch, because this landmark region did not dilate during AngII infusion.
Results: Luminal diameters of the suprarenal aorta did not change significantly in saline-infused mice over 28 days of
measurement (P  .71). In contrast, AngII infusion led to rapid dilation of suprarenal aortas during the initial 7 days of
infusion (0.071mm/d; P .0037 for the change in the initial expansion rate). Further luminal diameter expansions occurred
for the remaining 21 days of observation at a more modest rate (0.023 mm/d; P  .0001 for continued expansion after day
7). Within the initial 14 days of AngII infusion, some apoE/mice died as a result of rupture of the aorta in the suprarenal
region. We had previously assumed that aortic dilation and rupture occurred simultaneously. However, in the AngII-infused
mice that succumbed to aortic rupture, luminal diameters increased several days before death.
Conclusions: High-frequency ultrasonography demonstrated that suprarenal aortic expansion occurs rapidly after the
initiation of AngII infusion into apoE/ mice. (J Vasc Surg 2006;44:372-6.)
Clinical Relevance: Angiotensin II has been inferred to have an important role in the development of human aortic
diseases. Infusion of angiotensin II into mice leads to the development of abdominal aortic aneurysms. Definition of the
natural history of abdominal aortic aneurysm development in animal models of the disease may provide insight into the
factors associated with initiation and propagation in the human disease. The recent development of high-frequency
ultrasonography has permitted the sequential noninvasive detection of mouse aortic luminal dimensions during
angiotensin II infusion. The convergence of studies on aortic dimensions, in association with pathologic characterization
of the tissue, should provide a means to define mechanisms of abdominal aortic aneurysm formation.Infusion of angiotensin II (AngII) via subcutaneous os-
motic minipumps leads to the development of abdominal
aortic aneurysms (AAAs) in low-density lipoprotein recep-
tor/  and apolipoprotein E (apoE)/ mice.1-10 AngII
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372infusion also promotes AAAs in normolipidemic mice, albeit
with a lesser incidence.11 The development of AngII-induced
AAAs is a complex process.12 On the basis of pathologic
analysis of aortic tissues acquired at different intervals of AngII
infusion, the initial discernible change in the aneurysm-sus-
ceptible region is medial macrophage accumulation. This pre-
cedes a transmedial break that produces luminal dilation. The
ensuing thrombus formation at the site of aortic dilation
promotes an inflammatory response that predominantly in-
volves the innate immune system. The aorta is gradually
remodeled, with increased deposition of extracellular matrix
and formation of atherosclerotic lesions.12 In some mice in-
fused with AngII, death occurs within the first 14 days as a
result of aortic rupture in the suprarenal region.
Currently, the quantification of AngII-induced AAAs
requires the death of the mouse and acquisition of the
aortic tissue for AAA analysis using intact ex vivo or sec-
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to AAA formation in mice would be enhanced by the
availability of noninvasive techniques. Previous approaches
have used nondestructive techniques such as transrectal
ultrasonography.13 Ultrasonic imaging of AngII-induced
AAAs has been attempted previously, but available instru-
ments were not optimal for the small dimensions of mouse
aortas.3 Recently, a high-frequency ultrasound machine has
become commercially available that has characteristics ame-
nable to imaging mice. The Visualsonics Vevo 660 (Visu-
alsonics Inc, Toronto, Ontario, Canada) machine uses
probes with a sufficiently high frequency of 40 MHz to
permit a resolution of 30 m at a focal length of 6 mm.
These characteristics have the capability of imaging the
abdominal aorta in mice. The practical application of this
instrument to quantify changes in the dimensions of the
abdominal aorta of mice in vivo has been demonstrated
recently by Martin-McNulty et al.14
Using this instrument, we performed a validation pro-
cess to measure aortic dimensions and determine intrauser
and interuser variability in this measurement. High-
frequency ultrasonography was then used to quantify the
temporal evolution of luminal aortic expansion in the su-
prarenal region of AngII-infused male apoE/ mice,
which have a high propensity to develop AAAs.15 These
studies demonstrated that the aortic expansion occurred
rapidly after the initiation of AngII infusion. In addition, an
unanticipated finding was that death due to aortic rupture
occurred several days after luminal dilation.
MATERIALS AND METHODS
Mice. Male ApoE/mice (bred in house from stock
originally obtained from the Jackson Laboratory, Bar Har-
bor, ME; 10 times backcrossed into the C57BL/6 back-
ground), 8 to 12weeks old, were housed in a pathogen-free
environment. Water and regular mouse diet were available
ad libitum. Three separate groups of apoE/ mice were
used to acquire data. All procedures were approved by the
Institutional Animal Care and Use Committee at the Uni-
versity of Kentucky.
Infusions. Alzet (Durect Corp; Cupertino, CA) os-
motic pumps (model 2004) were filled with either AngII
(infusion rate of 1000 ng · kg1 · min1) or saline, as
described previously.1,2 Pumps were implanted subcutane-
ously on the right flank via an incision in the scapular
region. Mice were observed twice daily after the implanta-
tion of pumps.
Ultrasound imaging. The high-resolution ultra-
sound imaging system performed two-dimensional imag-
ing (B mode) by using a real-time microvisualization scan-
head (RMV704) with a central frequency at themechanical
transducer of 40MHz (frame rate of 30 Hz), a focal length
of 6 mm, and an 8  8-mm field of view (Visualsonics;
Toronto, Canada).
To perform ultrasound scans, mice were anesthetized
with a mixture of ketamine and xylazine, and hair was
removed from the abdomen by using a depilatory cream
(Nair; Church & Dwight Co, Inc; Princeton, NJ). Micewere laid supine on a heated table, and warmed ultrasound
transmission gel was placed on the abdomen. Short-axis
scans of aortas were performed on the abdominal aorta
from the level of the left renal arterial branch through to the
suprarenal region. Aortic images were acquired at selected
intervals (0, 2, 5, 7, 12, 16, 21, and 28 days) after the
initiation of infusions. Cine loops of 300 frames were
acquired throughout the renal region of the abdominal
aorta and used to determine the maximal diameters of the
abdominal aorta in the suprarenal region. To define user
variability, three operators independently acquired and an-
alyzed images from the same group of mice to calculate the
coefficient of variation.
Aortic tissue acquisition. Twenty-eight days after
implantation of the pumps, sedated mice were killed and
perfused briefly with saline at a pressure of approximately
100 mmHg, followed by prolonged infusion with parafor-
maldehyde (4% wt/wt solution in phosphate-buffered sa-
line). Photographs were acquired of aortas in situ. Some
suprarenal aortas were sectioned at 10 m throughout the
region (8-10 mm). Sections were visualized after staining
with hematoxylin, and aortic lumen dimensions were mea-
sured with Image-Pro (Media Cybernetics Inc; Silver
Springs, MD). Necropsies were performed on all mice that
died during the 28-day infusion interval, to determine the
cause of death.
Statistics. Summary data are expressed as mean 
SEM. To quantify the relationship of aortic measurements
in vivo and ex vivo, linear regression was used (SigmaStat;
Point Richmond, CA). A linear mixed model was fit to the
aortic diameter data by using version 8.2 of SAS (SAS
Institute, Cary, NC). In particular, the mean aortic diame-
ter was modeled as a quadratic function of time. Estimates
of model parameters were used to make inferences about
the time courses of dilation. For all analyses, P  .05 was
considered to be statistically significant.
RESULTS
To reproduce the recent results of Martin-McNulty et
al,14 we performed initial studies in which the lumen diam-
eters of aortas were determined in saline- and AngII-
infused mice by using both an ultrasound approach in vivo
and a pathologic analysis of the vessel at necropsy. Exam-
ples of the ultrasonic images obtained by this approach are
shown in Fig 1 with photographs of the corresponding
aortas. The coefficient of variance in luminal diameter
measurements of the suprarenal aorta among operators was
7.64%  0.94% during saline infusion and 8.45%  1.09%
during AngII infusion. These measurements were recorded
in a nongated mode that did not take into account the
pulsatile nature of the aorta. In highly dilated aortas, a
contribution to variance is the level of difficulty in sharply
delineating the lumen/aortic wall boundary in grossly dis-
eased vessels. However, these variances were relatively mi-
nor compared with the extent of lumen dilation that occurs
during AngII infusion.
To quantify the fidelity of the aortic measurements by
ultrasonography, we performed studies similar to those
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analyzed the lumen dimensions by both ultrasound and
histologic analysis of the same regions. This comparison of





Fig 1. Measurement of murine aortic luminal dimens
apolipoprotein E/ mice infused with either saline (lef
acquire images are indicated on these photographs. Sam
regions are shown (A and C, suprarenal region; B andD
lumen is outlined by yellow dotted lines.ultrasonography and on tissue sections is shown in Fig 2. Inaccord with Martin-McNulty et al, there was a close agree-
ment between ultrasound and histological measurements (r
 0.9897).
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ments of aortic diameters were recorded at frequent inter-
vals over the 28-day infusion period. In saline-infused mice
(n  8), there was no significant change in the dimensions
of suprarenal aortas (P  .71; Fig 3). In addition, there was
no change in abdominal aortic luminal diameters at the
level of the left renal arterial branch, where dilations do not
occur during AngII infusion (data not shown). In contrast,
AngII promoted a prompt expansion of lumen diameters of
suprarenal aortas of apoE/mice. In the mice that devel-
oped AAAs and survived throughout the infusion interval
(n  12), the expansion rate of the luminal diameter was
greatest during the first 7 days (0.071 mm/d; P  .0037
for the change in the initial expansion rate). The rate of
increase in aortic luminal diameters was more modest dur-
ing the remaining 21 days, but expansion persisted
Fig 2. Comparison of aortic lumen measurements acquired in
vivo by ultrasonography and ex vivo by histology. Apolipoprotein
E/ mice infused with either saline or angiotensin II for 28 days
were subjected to ultrasonography to determine the maximum
lumen diameter in the suprarenal region. At the termination of the
study, mice were perfusion-fixed at approximately 100 mm Hg,
and their entire suprarenal aortas were sectioned to determine the
region of maximal dilation. Points represent the maximal lumen
diameter for individual mice for ex vivo and in vivo measurements.
The two measurements were highly correlated with each other (r
 0.9897).
Fig 3. Sequential measurements of abdominal aortic luminal di-
ameters of apolipoprotein E/ mice during infusion with either
saline or angiotensin II (AngII). Mice were infused with saline or
AngII for 28 days and monitored at frequent intervals. Data are
shown for AngII-infused mice that developed abdominal aortic
aneurysms and survived the infusion period. Abdominal aortic
luminal diameters were measured in the suprarenal region of mice
infused with saline (triangles; n  8 at all time points) or AngII
(circles; n 12). Data are based on the measurement of diameters
at each time point by at least two independent operators. Symbols
represent means, and bars represent SEMs.throughout the infusion period (0.023 mm/d; P  .0001for the continued expansion rate after day 7; Fig 3). This
mode of aortic expansion occurs irrespective of the magni-
tude of the diameter increase of the aorta at 28 days (data
not shown).
As noted previously,12,16 infusion of AngII into hyper-
cholesterolemic male mice results in some mortality within
the initial 14 days; this is usually attributable to rupture of
the suprarenal aorta. In this study, death due to aortic
rupture within this interval occurred in eight AngII-infused
mice (40% incidence). On the basis of previous pathologic
characterization of evolving AAAs,12 we had assumed that
the transmedial breaks, luminal dilation, and aortic rupture
in this region were simultaneous events. However, in the
course of this study, we observed that the luminal diameters
of suprarenal aortas of several mice expanded before mice
died by aortic rupture. Figure 4 represents examples of the
aortic diameters of mice that subsequently died from aortic
rupture in the suprarenal region. All these mice had dis-
cernible aortic dilations before aortic rupture. In some
cases, the aortic dilation occurred many days before the
rupture.
DISCUSSION
This study used a high-frequency ultrasound tech-
nique14 to determine the changes in aortic dimensions
during the infusion of saline or AngII into hypercholester-
olemic mice. In addition, we demonstrated that this tech-
nique can be performed with relatively small intraindividual
and interindividual variance; this further supports the valid-
ity of the measurements. Using this approach, we deter-
mined that the dilation of the suprarenal abdominal aorta
during AngII infusion occurred rapidly. This study also
determined that the occasional AngII-induced fatal aortic
rupture in this region occurs subsequent to luminal dila-
tion.
Our previous study characterized temporal pathologic
features of AngII-induced AAAs as determined by the
acquisition and staining of tissues at selected intervals after
initiation of AngII.12 These results implied that AngII-
infused AAAs were initiated by macrophage accumulation
in the medial layer of the suprarenal aorta that preceded
Fig 4. Lumen diameters of the suprarenal aortas of angiotensin
II–infused mice that subsequently died of abdominal aortic rup-
ture. Each curve represents an example of temporal changes in
luminal diameters of individual mice. In all of these examples,
aortic rupture of the suprarenal region occurred 1 or 2 days after
the final luminal measurement.transmedial breaks, luminal dilation, and subsequent
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excised tissues from a relatively small number of mice that
were killed at selected intervals. This previous study impli-
cated that there were rapid pathologic changes of the
suprarenal aorta during AngII infusion. The current study
used a noninvasive technique that was amenable to sequen-
tial measurement of the aortic luminal dimensions of a large
number of mice. This technique demonstrated that the rate
of aortic lumen expansion is rapid, with the greatest rate of
dilation occurring during the first 7 days. Thereafter, the
aortic lumen diameter expanded at a slower rate. These data
also demonstrated that the AAA size at the termination of
the infusion interval was largely determined by the extent of
expansion in this early phase. These results demonstrate
that the lumen diameter determined noninvasively by ul-
trasonography can be used as a measure of both AAA
incidence (percentage increase over baseline) and severity
(absolute magnitude of lumen diameter).
Several studies have demonstrated that infusion of
AngII into hyperlipidemic mice can lead to death, usu-
ally in the first 14 days, as a result of rupture of the
suprarenal aorta. The rupture is usually in the retroperi-
toneal region on the left side of the suprarenal aorta and
leads to death as a result of exsanguination. We had
previously assumed that aortic rupture occurred simulta-
neously with a transmedial break.12 This was based on
the premise that aortic rupture occurred because of the
inability of the adventitia to constrain blood after forma-
tion of a transmedial break. However, we were surprised
to find that dilation of the suprarenal aorta preceded
aortic rupture by several days. Thus, on the basis of the
ultrasonic characterization of these mice, aortic rupture
occurred in the region of luminal dilation, but it was
precipitated by a mechanism that occurred subsequent to
the transmedial breaks.
In conclusion, high-frequency ultrasonography has
enabled the quantification of the rapid expansion of
suprarenal aortic luminal dimensions in response to
AngII infusion. The elucidation of the mechanism of this
rapid AngII-induced dilation will provide insight into
the processes of AAA initiation.
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